Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate
ConclusionThe PD-L1 22C3 antibody concentrate can potentially be used with the laboratory-developed test on three commercially available immunohistochemistry staining platforms to determine PD-L1 expression in tumor samples from patients with gastric or gastroesophageal junction adenocarcinoma.
Source: Molecular Diagnosis and Therapy - Category: Molecular Biology Source Type: research
More News: Adenocarcinoma | Gastric (Stomach) Cancer | Gastroenterology | Laboratory Medicine | Molecular Biology | Pathology | Study